ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3030

Evidence of Inflammasome Activation in the Peripheral Blood and Salivary Gland Tissues of Primary Sjögren’s Syndrome Patients: Correlation with Clinical Indices of Severe Disease and Lymphoma Development

Aglaia G Vakrakou1,2, Sorina Boiu3,4 and Menelaos N Manoussakis1,5, 1Hellenic Pasteur Institute, Athens, Greece., Hellenic Pasteur Institute, Athens, Greece, Athens, Greece, 2Department of Pathophysiology, Department of Pathophysiology, School of Medicine, University of Athens, Greece, Athens, Greece, 3Department of Pathophysiology, School of Medicine, University of Athens, Greece, Athens, Greece, 4Hellenic Pasteur Institute, Athens, Greece, Athens, Greece, 5Department of Pathophysiology, School of Medicine, University of Athens, Greece, Department of Pathophysiology, School of Medicine, University of Athens, Greece, Athens, Greece

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Sjogren's syndrome and inflammasome activation

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Sjögren's Syndrome I: Clinical Insights

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:  Inflammasomes are intracellular multiprotein complexes that sense pathogenic microorganisms, as well as danger signals released following tissue injury. Such activation of inflammasome leads to the upregulation of various inflammasome-related molecules and the release of pro-inflammatory cytokines, namely interleukin-1β (IL-1β) and interleukin-18 (IL-18). In this study, we sought to investigate the inflammasome activation status in the peripheral blood and the salivary gland (SG) tissues of SS patients and its relationship with indices of disease activity and severity.

Methods:  PBMC mRNA expression of inflammasome-related molecules NLRP3, AIM2, ASC, pro-caspase-1, IL-1β, IL-18 as well as the interferon type I signature genes MX1 and IF44L was evaluated by RT-PCR. Serum expression of inflammasome proteins ASC, IL-1β and IL-18 was evaluated by ELISA. SG biopsies were examined for the presence of inflammasome-related proteins by confocal microscopy.

Results: Compared to healthy controls (n=20), SS patients exhibited significantly higher serum levels of ASC (n=56; p=0.002), IL-1β (n=37; p=0.003) and IL-18 (n=33; p<0.0001). The serum levels of ASC protein were significantly higher in SS patients at high risk for lymphoma development (SS-type I; n=17) and in SS patients with lymphoma (n=28), compared to SS patients with low risk for lymphoma development (SS-type II; n=11, for p=0.030 and p=0.004, respectively). In SS patients, the serum levels of ASC and IL-18 correlated positively with the total cumulative ESSDAI score values (p=0.005 and p=0.006, respectively), whereas ASC levels correlated with the presence of C4 hypocomplementemia (p=0.002), rheumatoid factor (p=0.02) and purpura (p=0.02). In addition, compared to healthy controls (n=16), the PBMC of SS patients expressed significantly higher levels of ASC, NLRP3, IL-1β, IL-18 and pro-caspase-1 transcripts (n=39, p<0.05). The calculation of the NLRP3-inflammasome score in PBMC indicated an optimal discrimination between SS clinical subgroups (AUC=0.915) and positively correlated with interferon type I expression (Spearman r=0.443, p= 0.0006, n=37). In the SG tissues of SS patients, CD68+ macrophages and epithelial cells manifested high expression of ASC protein that was localized in perinuclear aggregates (specks), suggesting inflammasome activation. Co-localization experiments showed significantly increased ASC expression in CD68+ macrophages in SS (p<0.0001), compared with non-SS control patients.

Conclusion:  Our findings indicate that SS patients manifest evidence of inflammasome activation in both peripheral blood and the SG tissues. Several indices of inflammasome activation correlated with the presence of severe disease, as well as lymphoma development and may constitute valuable clinical biomarkers for these patients.


Disclosure: A. G. Vakrakou, None; S. Boiu, None; M. N. Manoussakis, None.

To cite this abstract in AMA style:

Vakrakou AG, Boiu S, Manoussakis MN. Evidence of Inflammasome Activation in the Peripheral Blood and Salivary Gland Tissues of Primary Sjögren’s Syndrome Patients: Correlation with Clinical Indices of Severe Disease and Lymphoma Development [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/evidence-of-inflammasome-activation-in-the-peripheral-blood-and-salivary-gland-tissues-of-primary-sjogrens-syndrome-patients-correlation-with-clinical-indices-of-severe-disease-and-lymphoma/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evidence-of-inflammasome-activation-in-the-peripheral-blood-and-salivary-gland-tissues-of-primary-sjogrens-syndrome-patients-correlation-with-clinical-indices-of-severe-disease-and-lymphoma/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology